BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 35563547)

  • 1. Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway.
    Zhao J; Luo Z
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.
    Avruch J; Khokhlatchev A; Kyriakis JM; Luo Z; Tzivion G; Vavvas D; Zhang XF
    Recent Prog Horm Res; 2001; 56():127-55. PubMed ID: 11237210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.
    Li Y; Takahashi M; Stork PJS
    J Biol Chem; 2013 Sep; 288(38):27646-27657. PubMed ID: 23893412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAF-MEK-ERK pathway in cancer evolution and treatment.
    Ullah R; Yin Q; Snell AH; Wan L
    Semin Cancer Biol; 2022 Oct; 85():123-154. PubMed ID: 33992782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of regulating the Raf kinase family.
    Chong H; Vikis HG; Guan KL
    Cell Signal; 2003 May; 15(5):463-9. PubMed ID: 12639709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A-Raf: A new star of the family of raf kinases.
    An S; Yang Y; Ward R; Liu Y; Guo XX; Xu TR
    Crit Rev Biochem Mol Biol; 2015; 50(6):520-31. PubMed ID: 26508523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAF protein-serine/threonine kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
    Marais R; Light Y; Paterson HF; Marshall CJ
    EMBO J; 1995 Jul; 14(13):3136-45. PubMed ID: 7542586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dimerization-dependent mechanism drives RAF catalytic activation.
    Rajakulendran T; Sahmi M; Lefrançois M; Sicheri F; Therrien M
    Nature; 2009 Sep; 461(7263):542-5. PubMed ID: 19727074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway.
    Coles LC; Shaw PE
    Oncogene; 2002 Mar; 21(14):2236-44. PubMed ID: 11948406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages.
    Büscher D; Hipskind RA; Krautwald S; Reimann T; Baccarini M
    Mol Cell Biol; 1995 Jan; 15(1):466-75. PubMed ID: 7799956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.